Wet Macular Degeneration
51
2
4
34
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
15 trials with published results (29%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.8%
5 terminated out of 51 trials
87.2%
+0.6% vs benchmark
33%
17 trials in Phase 3/4
44%
15 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 34 completed trials
Clinical Trials (51)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
LEAP Strategy for Neovascular Age-Related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Optimizing the Treatment Strategy for Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy